vTv Therapeutics Inc. (VTVT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, vTv Therapeutics reported revenue of $0, down 100.0% from $1.0M the year before. Net income was -$27.0M, or -$3.20 per diluted share. Operating activities generated -$25.3M of cash. At fiscal year end, vTv Therapeutics held $89.9M in total assets against $25.5M in total liabilities, including $88.9M of cash and equivalents.
Open the full interactive vTv Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
vTv Therapeutics Key Stats
| Share Price | $28.23 |
|---|---|
| Market Cap | $350.3M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $20.23 – $42.72 |
| Shares Outstanding | 12.4 million (basic, 2026 Q2) |
vTv Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.4M | $4.0M | $2.0M | $0 | $1.0M | $0 |
| Operating Income | -$11.9M | -$21.7M | -$22.5M | -$25.5M | -$24.2M | -$32.8M |
| Pre-Tax Income | -$12.8M | -$17.6M | -$24.9M | -$26.0M | -$22.6M | -$31.1M |
| Income Tax | -$4.3M | $115,000 | $200,000 | $0 | $100,000 | $0 |
| Net Income | -$8.5M | -$13.0M | -$19.2M | -$20.2M | -$18.5M | -$27.0M |
| Diluted EPS | -$7.21 | -$8.55 | -$10.40 | -$9.71 | -$3.20 | -$3.20 |
vTv Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $36.8M | $0 |
| Net Income | -$8.7M | -$7.1M | $24.1M | -$13.1M |
| Diluted EPS | -$1.08 | -$0.85 | $1.65 | -$1.05 |
vTv Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.7M | $13.4M | $12.1M | $9.4M | $36.7M | $88.9M |
| Current Assets | $7.2M | $15.6M | $27.1M | $10.7M | $38.1M | $89.9M |
| Total Assets | $14.8M | $25.5M | $33.2M | $11.0M | $38.3M | $89.9M |
| Current Liabilities | $6.4M | $8.5M | $7.7M | $10.6M | $5.2M | $6.6M |
| Total Liabilities | $11.0M | $10.3M | $27.4M | $29.6M | $24.0M | $25.5M |
| Shareholders' Equity | -$80.1M | -$9.7M | -$10.7M | -$24.7M | $12.2M | $64.4M |
vTv Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$18.0M | -$19.3M | -$16.0M | -$19.1M | -$25.3M | -$25.3M |
| Cash From Investing | — | — | -$21,000 | $4.4M | $0 | $0 |
| Cash From Financing | $19.5M | $27.0M | $14.8M | $12.0M | $52.6M | $77.4M |
| Free Cash Flow | -$18.1M | -$19.4M | -$16.0M | -$19.1M | -$25.3M | — |
Figures from vTv Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full vTv Therapeutics financials page for every line item.
vTv Therapeutics Company Profile
| Ticker | VTVT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | High Point, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001641489 |
Frequently Asked Questions
What was vTv Therapeutics' revenue in fiscal 2025?
vTv Therapeutics (VTVT) reported revenue of $0 for fiscal 2025.
What is vTv Therapeutics' annual revenue history?
vTv Therapeutics' annual revenue by fiscal year: 2020: $6.4M; 2021: $4.0M; 2022: $2.0M; 2023: $0; 2024: $1.0M; 2025: $0.
What was vTv Therapeutics' net income in fiscal 2025?
vTv Therapeutics reported net income of -$27.0M for fiscal 2025.
What was vTv Therapeutics' earnings per share (EPS) in fiscal 2025?
vTv Therapeutics' diluted EPS was -$3.20 for fiscal 2025 (adjusted for any later stock splits).
What was vTv Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), vTv Therapeutics reported revenue of $0.
How many shares of vTv Therapeutics are outstanding?
vTv Therapeutics reported a weighted average of 12.4 million basic shares outstanding in 2026 Q2.
What is vTv Therapeutics' market cap?
Based on its latest closing price, vTv Therapeutics (VTVT) has a market capitalization of about $350.3M.
When does vTv Therapeutics' fiscal year end?
vTv Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is vTv Therapeutics headquartered?
vTv Therapeutics lists its business address in High Point, North Carolina in its SEC filings.